ASXL1 and acute myeloid leukemia: Patients with high NADM8 scores were older and exhibited a higher frequency of specific gene mutations in the ELN adverse risk group (e.g., TP53, SF3B1, ASXL1, U2AF1), which were reported to be enriched in elderly AML patients (41–43).